CDK5 inhibition in vitro and in vivo induces cell death in myeloma and overcomes the obstacle of bortezomib resistance

The emergence of new drugs is a major feature of the treatment history of multiple myeloma (MM), which also reflects the current incurability of MM. As a unique member of cyclin dependent kinase (CDK) family, CDK5 participates in numerous tumorigenic or non-tumorigenic processes. The aim of this stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Hailong, Xu, Li, Cen, Xi, Yang, Li, Feng, Juan, Li, Guang, Zhu, Huafeng, Gao, Shan, Yu, Yan, Zhao, Yaping, Tian, Zhiqiang, Hou, Liping, Yu, Shuchun, Gao, Guangxun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169959/
https://www.ncbi.nlm.nih.gov/pubmed/32236619
http://dx.doi.org/10.3892/ijmm.2020.4553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169959/
https://www.ncbi.nlm.nih.gov/pubmed/32236619
http://dx.doi.org/10.3892/ijmm.2020.4553

Ejemplares similares